Form 4: Chemours Director Boosts Stake with Deferred Stock Units

Chemours Director Livingston Satterthwaite acquired 1,298 deferred stock units, increasing his beneficial ownership to 4,615.309 units, as part of a pre-arranged plan.

Summary

• Livingston Satterthwaite, a Director of The Chemours Company (CC), acquired 1,298 Deferred Stock Units (DSUs).
• The transaction date for this acquisition is reported as December 31, 2025.
• Each DSU is the economic equivalent of one share of Chemours' common stock and was valued at $11.79.
• Following this transaction, Mr. Satterthwaite beneficially owns a total of 4,615.309 derivative securities, which include deferred stock units and dividend equivalent units.
• The DSUs become payable upon the second calendar year following Mr. Satterthwaite's termination of service as a director.
• This transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer, intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 6

Explanation: The acquisition of deferred stock units by a director, especially under a 10b5-1 plan, is generally viewed as a neutral to slightly positive signal, indicating continued alignment of interests with shareholders and a planned compensation structure, rather than a direct vote of confidence via open market purchase.

Positives

• A director increasing their beneficial ownership, even through deferred compensation, can signal confidence in the company's future performance.
• The transaction being part of a Rule 10b5-1 plan indicates a pre-planned, systematic approach to compensation or investment, reducing concerns about opportunistic timing.

Negatives

• The compensation is in deferred stock units, meaning the director does not receive immediate cash or freely tradable shares.
• The payment of the DSUs is contingent on the director's termination of service, which means the value is not realized until a future, unspecified date.

Risks

• The value of the deferred stock units is tied to the future performance of Chemours' common stock, exposing the director to market risk.
• There is a risk that the director's service could terminate under unforeseen circumstances, affecting the timing and value of the payout.

Future Outlook

The deferred stock units will become payable upon the second calendar year following the reporting person's termination of service as a director, linking future compensation to continued service and the company's stock performance.

Industry Context

The acquisition of deferred stock units is a common form of equity compensation for directors in publicly traded companies, aligning their interests with long-term shareholder value. The use of a Rule 10b5-1 plan is standard practice for insiders to manage stock transactions in compliance with insider trading regulations.

Related Party Transactions

• The acquisition of deferred stock units by a director from the company constitutes a related party transaction as it involves compensation between the company and a member of its board.

Stakeholder Impact

• Shareholders: The transaction aligns the director's long-term interests with those of shareholders, as the value of the DSUs is tied to the company's stock performance.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The deferred stock units will become payable upon the second calendar year following the Reporting Person's termination of service as a director.

Key Dates

Keywords

Chemours, CC, Deferred Stock Units, DSU, Insider Transaction, Form 4, Director Compensation, Equity Compensation, 10b5-1 Plan